Amylin Pharma (AMLN) Reports Q4 GAAP Loss of $3.15/Share
AMLN Hot Sheet
EPS Growth %: +4.2%Financial Fact:
Research and development: 51.24M
Today's EPS Names:
TARO, BRLI, TLB, More
Amylin Pharmaceuticals, Inc. (NASDAQ: AMLN) reported Q4 GAAP loss of $3.15, which does not compare to the analyst estimate of ($0.08). The company posted a loss per share of 13 cents during the same quarter last year. Revenue for the quarter came in at $164.9 million versus the consensus estimate of $163.64 million.
For earnings history and earnings-related data on Amylin Pharmaceuticals, Inc. (AMLN) click here.
Get immediate access to market moving news and alerts with StreetInsider.com Premium - FREE TRIAL!
For earnings history and earnings-related data on Amylin Pharmaceuticals, Inc. (AMLN) click here.
Get immediate access to market moving news and alerts with StreetInsider.com Premium - FREE TRIAL!
You May Also Be Interested In
- UPDATE: Bristow Group (BRS) Reports Better-Than-Expected Q4 Results; Offers FY13 Outlook
- Today's Economic Outlook - Report Highlights Amylin Pharmaceuticals, Inc. and Wal-Mart Stores, Inc.
- UPDATE: Lowe's (LOW) Beats Q1 Views Amid Lagging Seasonal Demand; Issues Light FY12 Earnings Outlook
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
